LAURA：同步/序贯放化疗后奥希替尼在 III 期 EGFR 突变 NSCLC

类型: 论文 发表日期: 2024-06-02 入库日期: 2026-05-21 来源: NEJM / PubMed 标签: EGFR L858R, 奥希替尼, LAURA, 局部晚期, 放化疗

Citation

Lu S, Kato T, Dong X, et al. Osimertinib after Chemoradiotherapy in Stage III EGFR-Mutated NSCLC. New England Journal of Medicine. 2024. DOI: 10.1056/NEJMoa2402614

Why this is in CCL

Mom is stage IV rather than unresectable stage III, so this is not directly applicable. It is still useful background because it shows how strongly osimertinib has moved across EGFR-mutated NSCLC stages and helps frame questions about local therapy plus systemic EGFR control.

Key takeaways

• Population: unresectable stage III EGFR-mutated NSCLC without progression after chemoradiotherapy.
• Strategy: osimertinib maintenance after definitive CRT.
• Relevance is contextual, especially when discussing local control of oligoprogressive lesions.

Practical relevance

• Do not use as direct evidence for metastatic maintenance decisions.
• Keep as background for radiation/local-control discussions, especially if doctors consider treating selected progressing lesions while maintaining systemic therapy.